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Annual Outpatient Hysteroscopy and Endometrial Sampling (OHES) in 
HNPCC/ Lynch Syndrome (LS) 
 
Introduction and background  
Lynch Syndrome (LS) or HNPCC is a heritable syndrome caused by a mutation in 
one of the DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6, and PMS2.[1] 
Strict family history based diagnostic criteria (Amsterdam Criteria (AC)-II)[2] are 
used to identify people at increased risk. LS women have a 40-60% life time risk for 
endometrial cancer (EC). Some data suggest EC risk may be higher than that of 
colorectal cancer (CRC)[3,4] and greater for MSH2 and MSH6 than for MLH1 
carriers.[5,4,6,3]  
Gynaecological surveillance with endometrial sampling has been recommended from 
30-35 years age in women who wish to delay/avoid risk-reducing surgery.[5,7] 
Unlike screening for CRC, the efficacy of EC screening remains unproven with only 
a handful of published series evaluating different modalities for EC screening in LS. 
These include: (a) Transvaginal (TVS) and/or transabdominal ultrasound;[8-10]; (b) 
TVS and endometrial sampling;[11,9] and (c) Hysteroscopy.[12,13]  
 
The possibility of using hysteroscopy  as a screening modality in LS was initially 
suggested in 2002.[14] However, no screen detected cancers have been reported in 
the published literature  In this paper we report on our initial experience of annual 
outpatient hysteroscopy and endometrial sampling (OHES) as a screening strategy for 
EC in women with LS and compare it with TVS alone. 
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Methods 
The familial gynaecological cancer clinic at University College London Hospital is a 
tertiary clinic for managing women at ‘high-risk’ of gynaecological cancers. All 
women attending the clinic are managed by a multidisciplinary team, which includes 
gynaecological oncologists, clinical geneticist, clinical psychologist, radiologist, 
clinical nurse specialist, minimal access gynaecologist and pathologist. All women 
attending the clinic undergo detailed pedigree based risk-assessment and counselling. 
They receive comprehensive advice on advantages and disadvantages of risk-reducing 
surgery and screening, as well as reproductive and life style issues.  
 
High-risk women with LS are identified on the basis of the diagnostic AC-II 
criteria[2] or the presence of a MMR gene mutation. LS women >35-40 years, who 
have completed their family, are offered risk-reducing surgery: total laparoscopic 
hysterectomy (TLH), bilateral salpingo-oophorectomy (BSO) and peritoneal 
washings. Women >35 years are offered screening for ovarian cancer within the 
United Kingdom Familial Ovarian Cancer Screening Study (UKFOCSS).  
 
Since October-2007 eligible LS women attending the clinic are offered EC screening 
with TVS and OHES. Inclusion criteria are: LS women >30 years age. Exclusion 
criteria are: current pregnancy, prior hysterectomy, women opting for risk-reducing 
surgery or those negative on predictive testing for a known familial mutation. Women 
keep a menstrual calendar and undergo annual TVS with endometrial thickness (ET) 
measurement and OHES. TVS is performed by experienced ultrasonographers with 
over 10 years scanning experience. Hysteroscopy is carried out by one of a team of 3 
experienced hysteroscopists, in an office setting, as described previously.[15] 
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Endometrial sampling is undertaken in all women using guided biopsies/ polypectomy 
where indicated and/or a Pipelle device (Laboratoire C.C.D, France) at the end of the 
procedure.[15] Any irregular, heavy or unscheduled vaginal bleeding reported is 
investigated by bringing forward the annual OHES. Histological specimens are 
processed in total by a dedicated senior pathologist (EB). All data are stored on a 
bespoke database.  
 
The current analysis includes all OHES procedures between October-2007 and 
March-2010. The primary outcome was EC and atypical endometrial hyperplasia 
(AEH). Inclusion of AEH as an outcome was based on it being an established 
premalignant lesion, lack of concordance in the diagnosis of AEH or EC between 
pathologists,[16] and  42.6% of AEH having concurrent EC.[17] Wherever necessary, 
case notes, histopathology and TVS/biochemistry reports were reviewed. A screen 
positive on TVS is defined as (a) ET >5mm (measuring both endometrial layers): 
postmenopausal women,[18] (b) ET >12mm (measuring both endometrial layers in 
the second week of the cycle): premenopausal women,[10] (c) presence/suspicion of a 
polyp, or (d) irregular endometrium with fluid in the cavity. Although a cut off of 4 
mm for endometrial thickness has been used by some to triage symptomatic 
postmenopausal women for hysteroscopy, we use a cut off of 5mm in our practice, 
which is consistent with that advocated by a number of other institutions, a meta-
analysis[18] and systematic review.[19] In addition, our experience of modelling 
endometrial thickness in asymptomatic post-menopausal women indicates the best 
performance characteristic may be obtained at a cut off of 5.1mm.[20] Cut-offs for 
endometrial thickness in asymptomatic premenopausal women unlike those for 
postmenopausal women are not well-defined. The 12mm cut off was chosen on the 
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basis of an earlier published report in the literature which evaluated TVS for 
screening in these women.[10] A screen positive at OHES is defined by the histology 
report.  
 
Statistical analysis was undertaken using SPSS 12.0.1. The Mann-Whitney test was 
used to compare age distributions between groups after reviewing histograms. 
Fisher’s test was used to calculate the difference between proportions. Kaplan Meier 
curves and the Log Rank Test was used to evaluate any difference in time to 
diagnosis. Two sided p values are reported for all statistical tests.  Confidence 
intervals for a single proportion were calculated using the statistics package 
‘Measuring Usability’ (J Sauro) LLC, Denver, Colorado, USA. Sensitivity, 
specificity, negative predictive value (NPV), positive predictive value (PPV), negative 
likelihood ratio (NLR) and positive likelihood ratio (PLR) were used to compare the 
screening performance for TVS and OHES.  
 
Results 
Between March-2004 and March-2010, 69 women with LS (fulfilling AC-II )[2] 
attended the clinic, of whom 25 were known mutation carriers (12MLH1, 12MSH2, 
1PMS2). Thirteen women preferred risk-reducing surgery, five moved away, two 
were <30 years age and two tested negative for a familial mutation. The remaining 47 
women opted for EC screening. Four eventually declined OHES and two have an 
appointment scheduled (Figure-1). The characteristics of the remaining cohort (41) 
are described in Table-1.  
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Between October-2007 and March 2010, 41 prevalent and 28 incident screens (49.2 
women screen years) were performed. The screening outcomes of the cohort are 
described in Figure-1. There was one failed outpatient hysteroscopy procedure which 
was completed under a general anaesthetic.  
 
At prevalence screen, 39 were asymptomatic and 2 complained of irregular periods 
with intermenstrual bleeding. One of the symptomatic women (benign polyp) and 6 of 
the 39 (15.4%) asymptomatic women had an abnormal TVS (2 endometrial polyps, 3 
ET>12mm, 1 irregular endometrium/fluid in the cavity) of whom 1 (polyp) had EC at 
histology. Three asymptomatic women were detected to have EC/AEH on OHES. 
Two of these three women with EC/AEH, underwent hysterectomy because of 
prevalence screen detected EC/AEH and 6 women opted for risk-reducing surgery 
after their initial prevalent screen. TVS and OHES in these 6 women were normal.  
 
22 eligible women underwent incident screen-1 (Figure-1). Of these, 3 (13.6%) 
presented with abnormal bleeding at 9-11 months from last screen. One had an in-situ 
levonorgestrel intrauterine system (LNG-IUS, Mirena® Schering Health Care). None 
had EC/AEH. All three had a normal TVS. Of the 19(86.4%) asymptomatic women, 
TVS was abnormal in 5(26.3%) which included the one woman with EC. This woman 
underwent hysterectomy following incident screen detected EC. Six of the 22 incident 
screen-1 women, underwent a subsequent second incident screen (incident screen-2) 
during the study time-period (Figure-1). Of these five were asymptomatic with normal 
TVS. However, endometrial hyperplasia (EH) was found at OHES in two of these 
cases.  
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Overall 3 women (2 prevalence, 1 incident screen) had EC and one woman had AEH 
(prevalence screen) (Table-2). The latter includes one woman initially diagnosed as 
AEH who had a stage1a, grade1 EC at TLH BSO. Three of four women with screen 
detected endometrial pathology were MMR mutation carriers. No adjuvant treatment 
was needed for any of the three EC cases who remain recurrence free at 10, 16 and 22 
months follow-up respectively. The woman with AEH opted for conservative 
management with a LNG-IUS (Mirena®, Schering Health Care, UK). Follow-up 
OHES 4 months later was normal with no histological evidence of atypia/EC. No 
interval cancers have occurred in the cohort to date. 
 
Combining incident and prevalent screens, for EC/AEH, OHES had similar specificity 
89.8%(95%CI 79.2%, 96.2%) but higher  PLR 9.8(95%CI 4.6,21) and lower NLR (0 ) 
compared to  TVS: specificity 84.75%(95%CI 73%, 92.8%), PLR 3.28(95%CI 
1.04,10.35) and NLR 0.59(95%CI 0.22,1.58) (Table-3).  
 
The median age of women with EC/AEH was 40.9 years (IQR 5.3 years) and the 
median age for the rest of the screened cohort was 43 years (IQR 12.3 years). 
EC/AEH cases were not found to differ from the rest of the cohort with respect to 
mutation status (p=0.64), number of screens (p=0.70) or age (Mann Whitney, p=0.40). 
However, mutation carriers undergoing screening had a significantly younger median 
age (39.7years, IQR 6.3) than the remaining AC-II positive women (44.2years, 
IQR12.8) (p=0.022). Kaplan Meier and Log Rank analysis of time to diagnosis for 
EC/AEH did not show any difference between known MMR carriers and those 
fulfilling AC-II alone (p=0.85).  
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Additional pathology found in this cohort included 6 endometrial polyps (3 prevalent 
and 3 incident). The annual incidence rate was 3.57% (95%CI 0.1, 18.35) for 
EC/AEH, 10.71% (95%CI 2.27, 28.23) for polyps, 7.1% (95%CI 0.88, 23.5) for EH 
(Table-4).  
 
 
 
Discussion 
This is to our knowledge the first series reporting the diagnosis of early stage EC in 
asymptomatic LS women using hysteroscopy based screening. Our findings indicate 
that OHES has high specificity and PLR and low NLR. The higher annual incidence 
rate of EC in our cohort (3.57%; 95%CI 0.09,18.35) compared to the expected rate of 
approximately 1% in this population suggests that there may be lead time. OHES 
seems superior to TVS alone as a test for detecting EC/AEH in these women (Table-
3), with all four women with EC/AEH being detected by OHES compared to TVS 
which only detected two. The data further support the current guidelines that 
recommend that endometrial sampling should be undertaken in all LS women.[21,7] 
 
TVS alone had a PLR of 3.28 for EC/AEH and NLR of 0.59 for EC/AEH. In contrast, 
OHES achieved an overall PLR of 9.8 for EC/AEH and a NLR of 0. Likelihood ratio 
combines information about sensitivity and specificity to assess test performance. It is 
independent of prevalence and permits comparisons across different types of tests.  A 
value close to 1 has little clinical significance as the post-test probability (odds) of 
disease is little different from the pre-test probability. A PLR of >5 indicates 
moderate and >10 strong probability for disease being present when a test is positive.  
 - 8 - 
A PLR of >5 is generally a pre-requisite for adoption of a clinical test or procedure A 
NLR of <0.2 is moderately and <0.1 strongly indicative of the disease being absent. 
The results suggest that TVS alone as a screening test has poor ability to detect or rule 
out disease and is not very helpful in clinical decision making, while OHES has good 
diagnostic ability to detect disease and excellent ability to rule out disease in LS, 
making it an effective test for endometrial screening. For comparison the PLR and 
NLR for mammography are 9.4 and 0.19[22], and for CT pulmonary angiogram in 
diagnosing pulmonary embolism are 8.6 and 0.06 respectively.[23] OHES 
performance in asymptomatic women in our series is consistent with the previously 
reported performance in symptomatic women (PLR 60.9, NLR 0.15) for diagnosing 
EC,[24] with a negative hysteroscopy reducing EC probability to 0.6%.[24] 
 
TVS alone would have missed 2 of 4 cases of EC/AEH, and did not seem to add to 
the performance of OHES. Our findings are consistent with a previous series using 
TVS and endometrial sampling which found that 55%(6/11) of the screen detected 
EC, 50%(2/4) AEH and 50% of complex hyperplasia (4/8) cases had a normal 
TVS.[11] A majority of these false negative cases were post-menopausal. An increase 
in screen detected EC/AEH cases has been reported when TVS guided screening was 
replaced by a combined approach of TVS and endometrial sampling.[9] Overall our 
findings and these data suggest that in contrast to symptomatic postmenopausal 
general population women, the performance of TVS for detecting endometrial 
pathology in asymptomatic (pre and postmenopausal) LS women undergoing 
screening is poor. Reliable cut-offs for pre-menopausal and asymptomatic post-
menopausal LS women are unknown. Two previous series have compared TVS alone 
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to a combination of TVS and endometrial sampling and found the latter to be better at 
detecting EC/AEH.[9,11]  
 
There are limitations to use of Pipelle endometrial sampling alone, including 
variability in its performance with menopausal status and type of pathology.[25] 
Reliable performance characteristics in asymptomatic LS women (significant 
proportion of who are premenopausal) are not available. Cancers have been missed on 
Pipelle alone, with three of the 11 cases of EC not detected on endometrial sampling 
in a previous LS series.[11]  
 
The median age of our cohort was 42.9 (95%CI 39.4, 49.7) years. Known MMR 
carriers undergoing screening were significantly younger than those fulfilling AC-II 
alone. This may reflect increased screening awareness among gene carriers and 
increased uptake of preventative surgery by older mutation carriers. The median age 
(40.9 years, IQR38.3, 43.5) of women diagnosed with EC/AEH in our study is 
significantly lower than that reported in two previous series using TVS and 
endometrial sampling: (a) 51.5 years (IQR 47,54, p=0.016),[11] median age of the 
entire cohort not reported and (b) 51 years (IQR 46,55, p=0.008 Mann-Whitney) with  
median age of cohort  46 years.[9] Our median age at diagnosis is also lower than that 
reported in epidemiological data (48-50 years),[3,26] though it lies within the 
expected range (27-72 years) found in LS.[26,3] The small size of our data set makes 
it difficult to draw conclusions. If confirmed, age differences could be related to a 
combination of age and risk factor profile of our cohort and the lead time of 
screening. 
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The strengths of our study include a strict screening protocol with prospectively 
collected data, longitudinal follow-up and description of outcomes for both 
prevalence and incident screens. The main weakness is the small size of the cohort 
and the need for validation in larger multicentre studies. It is to be noted that previous 
reports on LS screening using hysteroscopy have involved up to 62 patients and no 
EC were detected. Although we have compared TVS and OHES, the standard practice 
in a number of institutions is screening using a combination of TVS and endometrial 
sampling. TVS alone has a poor detection rate for endometrial pathology. A limitation 
of our study is a lack of ability to directly compare OHES with TVS and endometrial 
sampling. Future research in this area should be directed towards addressing this 
issue. Given the small sample size in most centres, this will necessitate a multicentre 
international study. 
 
We are not aware of any reports on incidence rate of endometrial pathology in LS 
women. We found that 1 in 5 (incidence rate 21.4%; 95% CI 8.3, 40.1) LS women 
had endometrial pathology with an annual incidence of polyps of 11%. This included 
one women with adenocarcinoma in a polyp. Our findings are in keeping with 
randomised trials in the general population which have shown that TVS and Pipelle 
have lower sensitivity for focal lesions like polyps compared to hysteroscopy.[27,28] 
Hysteroscopy detects lesions which may be missed by both TVS and 
Pipelle[28,27,15] and also permits directed biopsy from a focal lesion. 
 
In the general population, up to 5% of non-atypical EH and 30% of AEH progress to 
EC.[29] It is unknown if the rates of progression are greater in the LS population with 
a much higher a priori risk for EC. We can speculate that subsequent EC may have 
 - 11 - 
been prevented or delayed in some of the cases of polyps/hyperplasia treated in our 
series. EC/AEH was found in 9.76% (95%CI 2.7, 23.1) cases which is consistent with 
reports in the literature,[11,10] though higher than rates reported in some 
series.[8,12,13]  
 
Both Hysteroscopy and Pipelle endometrial sampling are effective, easy to perform 
and well tolerated as outpatient procedures. Our failure rate of 1.45%(95%CI 
0.04,7.81) is consistent with those in systematic reviews (4.2%, 95%CI 3.9,4.5).[24] 
The compliance with annual screening suggests that this is acceptable. A recent study 
evaluating acceptability of screening, found no significant difference in pain scores 
between either hysteroscopy or endometrial sampling.[30] The efficacy and patient 
acceptability of OHES is similar to the in-patient procedure and the former is more 
cost-effective.[31,32] Preliminary data suggest that hysteroscopy-based endometrial 
screening in LS does not appear to be associated with any psychological 
morbidity.[33]  
 
Conclusion 
LS women have a high incidence of polyps, premalignant lesions and EC. Initial data 
suggest that an OHES based surveillance strategy has good performance 
characteristics for detecting early stage EC/AEH in LS and may be superior to that of 
TVS alone. However, definitive data would require a larger international study. The 
challenges are the relatively small numbers of LS women at individual centres, the 
rates of risk reducing surgery and differences in use of routine outpatient 
hysteroscopy between countries.  
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TABLES LIST 
Table 1: Characteristics and outcome of Lynch Syndrome (LS) women 
undergoing OHES screening for endometrial cancer 
 
*One patient had a MLH1 VUS (variant of uncertain significance) 
AC–Amsterdam Criteria, AEH-atypical endometrial hyperplasia, OHES-Outpatient 
Hysteroscopy and Endometrial Sampling, IQR-Interquartile range 
 
Table 2- Screening details in cases of screen detected abnormal endometrial 
pathology 
 
* Benign endometrial polyps were diagnosed at OHES alone on 2 consecutive screens  
** Diagnosis confirmed following total laparoscopic hysterectomy and bilateral 
salpingo-oophorectomy 
AEH-atypical endometrial hyperplasia, BSO-Bilateral salpingo-oophprectomy; EC-
Endometrial cancer; EP-endometrial polyp; ECxP-endocervical polyp; Gr-Grade, 
OHES -Outpatient Hysteroscopy and Endometrial Sampling; P-prevalent screen; I-
incident screen; MMR-mismatch repair gene, TLH-Total Laparoscopic Hysterectomy, 
VUS-variant of uncertain significance 
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Table-3: Performance Characteristics of OHES and TVS 
 
CI-confidence interval, FN-false negative, FP-false positive, I-incident, NLR-negative 
likelihood ratio, NPV-negative predictive value, OHES-Outpatient Hysteroscopy and 
Endometrial Sampling, P-prevalent, PLR-positive likelihood ratio, PPV-positive 
predictive value, TN-true negative, TP-true positive, TVS-transvaginal scan 
 
Table 4- Abnormal pathology rates (per patient) at Prevalent and Incident 
screening in the cohort 
 
* Endometrial polyps diagnosed on 2 consecutive screens in one case 
** One case with endometrial cancer also had a malignant endometrial polyp 
# Includes 22 women, 6 of whom underwent a third round of annual screening 
 
Figure 1 legend: Consort flow chart for the cohort 
 
AEH-Atypical endometrial hyperplasia, BSO-Bilateral salpingo-oophprectomy, 
DNA-did not attend, EC-endometrial cancer, ECxP-endocervical polyp, EH-
endometrial hyperplasia, EP-endometrial polyp, LS- Lynch Syndrome, N-normal, 
OHES-Outpatient Hysteroscopy and Endometrial Sampling, Pos-positive, TLH-Total 
Laparoscopic Hysterectomy, TVS-transvaginal scan 
  
 
